Company intelligence / Profile preview
Rein Therapeutics
Austin, Texas, United Statesreintx.com ↗
- Ownership
- Public · RNTX
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
Rein’s lead candidate LTI-03 showed positive topline results in a Phase 1b trial in IPF patients, demonstrating dose-dependent effects on five biomarkers with four reaching statistical significance. The company plans to initiate a Phase 2 trial in the first half of 2025. Preclinical data support LTI‑03’s antifibrotic activity. LTI‑01 has completed early clinical trials for loculated pleural effusions and holds Orphan Drug Designation in the US/EU and Fast Track status from the FDA.
- Therapeutic areas
- PulmonologyRare Diseases
- Modalities
- Synthetic peptides (notably cell-permeating alpha-helical peptides and proenzymes)
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Request access →03
Partnerships
Pfizer collaboration on ALRN‑6924 + Ibrance for MDM2-amplified cancers (legacy Aileron partnership)Advancium Health Network option agreement for ALRN‑6924 oncology agent
04
Financials
- Market cap
- $21.8M
- Total revenue
- $0
- Enterprise value
- $-18.8M
Beyond the preview
Go deeper on Rein Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rein Therapeutics.